来迪派韦与索磷布韦联合治疗丙型肝炎病毒1型感染：系统评价与荟萃分析 - Suppr

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

作者信息

Rezaee-Zavareh Mohammad S, Hesamizadeh Khashayar, Behnava Bita, Alavian Seyed M, Gholami-Fesharaki Mohammad, Sharafi Heidar

机构信息

Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran.

出版信息

Ann Hepatol. 2017 March-April;16(2):188-197. doi: 10.5604/16652681.1231562.

DOI:10.5604/16652681.1231562

PMID:28233739

Abstract

摘要

相似文献

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

Ann Hepatol. 2017 March-April;16(2):188-197. doi: 10.5604/16652681.1231562.

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.

Ann Hepatol. 2017 May-Jun;16(3):375-381. doi: 10.5604/16652681.1235480.

Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.

Antivir Ther. 2017;22(5):369-379. doi: 10.3851/IMP3083. Epub 2016 Sep 2.

Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.

Ann Hepatol. 2018 Aug 24;17(5):815-821. doi: 10.5604/01.3001.0012.3142.

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study.

Lancet Gastroenterol Hepatol. 2020 Oct;5(10):918-926. doi: 10.1016/S2468-1253(19)30417-0. Epub 2020 Jun 10.

Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.

Nephrology (Carlton). 2018 May;23(5):446-452. doi: 10.1111/nep.13050.

Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.

J Gastrointestin Liver Dis. 2020 Sep 9;29(3):385-390. doi: 10.15403/jgld-2448.

Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.

J Gastroenterol. 2017 Aug;52(8):986-991. doi: 10.1007/s00535-017-1310-9. Epub 2017 Jan 30.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.

引用本文的文献

An eco-friendly chemometrics assisted UV spectrophotometric method for simultaneous determination of sofosbuvir, simeprevir and ledipasvir in pharmaceuticals.

BMC Chem. 2025 Jun 2;19(1):156. doi: 10.1186/s13065-025-01528-9.

Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis.

Pathogens. 2022 May 29;11(6):626. doi: 10.3390/pathogens11060626.

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders.

Virol J. 2021 Oct 7;18(1):199. doi: 10.1186/s12985-021-01659-0.

Effectiveness, tolerability and safety of Direct Acting Antivirals in Mexican individuals with Hepatitis C virus genotype-1 and previous pegylated interferon and ribavirin therapy.

PeerJ. 2021 Sep 17;9:e12051. doi: 10.7717/peerj.12051. eCollection 2021.

An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease.

PLoS One. 2021 Feb 10;16(2):e0246594. doi: 10.1371/journal.pone.0246594. eCollection 2021.

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.

Value Health. 2020 Sep;23(9):1180-1190. doi: 10.1016/j.jval.2020.03.018. Epub 2020 Jul 20.

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study.

Caspian J Intern Med. 2020 Winter;11(1):41-46. doi: 10.22088/cjim.11.1.41.

Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6.

Biomed Res Int. 2019 Nov 11;2019:2301291. doi: 10.1155/2019/2301291. eCollection 2019.

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?

World J Hepatol. 2018 Sep 27;10(9):543-548. doi: 10.4254/wjh.v10.i9.543.

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.

Clin Gastroenterol Hepatol. 2018 Nov;16(11):1811-1819.e4. doi: 10.1016/j.cgh.2017.12.037. Epub 2018 Jan 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献